FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204165978> ?p ?o ?g. }

• W3204165978 abstract "Abstract Background Neuroblastoma (NB) patients with MYCN amplification or overexpression respond poorly to current therapies and exhibit extremely poor clinical outcomes. PI3K-mTOR signaling-driven deregulation of protein synthesis is very common in NB and various other cancers that promote MYCN stabilization. In addition, both the MYCN and mTOR signaling axes can directly regulate a common translation pathway that leads to increased protein synthesis and cell proliferation. However, a strategy of concurrently targeting MYCN and mTOR signaling in NB remains unexplored. This study aimed to investigate the therapeutic potential of targeting dysregulated protein synthesis pathways by inhibiting the MYCN and mTOR pathways together in NB. Methods Using small molecule/pharmacologic approaches, we evaluated the effects of combined inhibition of MYCN transcription and mTOR signaling on NB cell growth/survival and associated molecular mechanism(s) in NB cell lines. We used two well-established BET (bromodomain extra-terminal) protein inhibitors (JQ1, OTX-015), and a clinically relevant mTOR inhibitor, temsirolimus, to target MYCN transcription and mTOR signaling, respectively. The single agent and combined efficacies of these inhibitors on NB cell growth, apoptosis, cell cycle and neurospheres were assessed using MTT, Annexin-V, propidium-iodide staining and sphere assays, respectively. Effects of inhibitors on global protein synthesis were quantified using a fluorescence-based (FamAzide)-based protein synthesis assay. Further, we investigated the specificities of these inhibitors in targeting the associated pathways/molecules using western blot analyses. Results Co-treatment of JQ1 or OTX-015 with temsirolimus synergistically suppressed NB cell growth/survival by inducing G1 cell cycle arrest and apoptosis with greatest efficacy in MYCN-amplified NB cells. Mechanistically, the co-treatment of JQ1 or OTX-015 with temsirolimus significantly downregulated the expression levels of phosphorylated 4EBP1/p70-S6K/eIF4E (mTOR components) and BRD4 (BET protein)/MYCN proteins. Further, this combination significantly inhibited global protein synthesis, compared to single agents. Our findings also demonstrated that both JQ1 and temsirolimus chemosensitized NB cells when tested in combination with cisplatin chemotherapy. Conclusions Together, our findings demonstrate synergistic efficacy of JQ1 or OTX-015 and temsirolimus against MYCN-driven NB, by dual-inhibition of MYCN (targeting transcription) and mTOR (targeting translation). Additional preclinical evaluation is warranted to determine the clinical utility of targeted therapy for high-risk NB patients." @default.
• W3204165978 created "2021-10-11" @default.
• W3204165978 creator A5001658268 @default.
• W3204165978 creator A5015043082 @default.
• W3204165978 creator A5019692078 @default.
• W3204165978 creator A5031623380 @default.
• W3204165978 creator A5040357304 @default.
• W3204165978 creator A5040571502 @default.
• W3204165978 creator A5062655427 @default.
• W3204165978 creator A5067292776 @default.
• W3204165978 creator A5073488481 @default.
• W3204165978 date "2021-09-26" @default.
• W3204165978 modified "2023-10-16" @default.
• W3204165978 title "Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma" @default.
• W3204165978 cites W1823798038 @default.
• W3204165978 cites W1980396381 @default.
• W3204165978 cites W1988976358 @default.
• W3204165978 cites W2021764678 @default.
• W3204165978 cites W2065508488 @default.
• W3204165978 cites W2071491707 @default.
• W3204165978 cites W2093199938 @default.
• W3204165978 cites W2096439168 @default.
• W3204165978 cites W2098282574 @default.
• W3204165978 cites W2100293658 @default.
• W3204165978 cites W2109378990 @default.
• W3204165978 cites W2117559539 @default.
• W3204165978 cites W2120572492 @default.
• W3204165978 cites W2130925781 @default.
• W3204165978 cites W2151748280 @default.
• W3204165978 cites W2158389310 @default.
• W3204165978 cites W2161035023 @default.
• W3204165978 cites W2183670742 @default.
• W3204165978 cites W2345262650 @default.
• W3204165978 cites W2466354473 @default.
• W3204165978 cites W2571037022 @default.
• W3204165978 cites W2618869560 @default.
• W3204165978 cites W2624467319 @default.
• W3204165978 cites W2777333782 @default.
• W3204165978 cites W2779743226 @default.
• W3204165978 cites W2793376960 @default.
• W3204165978 cites W2794385660 @default.
• W3204165978 cites W2806421539 @default.
• W3204165978 cites W2811111314 @default.
• W3204165978 cites W2883731008 @default.
• W3204165978 cites W2890266060 @default.
• W3204165978 cites W2890836849 @default.
• W3204165978 cites W2905394489 @default.
• W3204165978 cites W2911580600 @default.
• W3204165978 cites W2945696330 @default.
• W3204165978 cites W2969025212 @default.
• W3204165978 cites W3004733773 @default.
• W3204165978 cites W3016219057 @default.
• W3204165978 cites W3123853262 @default.
• W3204165978 cites W3128122465 @default.
• W3204165978 cites W3138474425 @default.
• W3204165978 cites W4211147182 @default.
• W3204165978 cites W3023512313 @default.
• W3204165978 doi "https://doi.org/10.1186/s12885-021-08782-9" @default.
• W3204165978 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8474810" @default.
• W3204165978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34565342" @default.
• W3204165978 hasPublicationYear "2021" @default.
• W3204165978 type Work @default.
• W3204165978 sameAs 3204165978 @default.
• W3204165978 citedByCount "6" @default.
• W3204165978 countsByYear W32041659782021 @default.
• W3204165978 countsByYear W32041659782022 @default.
• W3204165978 countsByYear W32041659782023 @default.
• W3204165978 crossrefType "journal-article" @default.
• W3204165978 hasAuthorship W3204165978A5001658268 @default.
• W3204165978 hasAuthorship W3204165978A5015043082 @default.
• W3204165978 hasAuthorship W3204165978A5019692078 @default.
• W3204165978 hasAuthorship W3204165978A5031623380 @default.
• W3204165978 hasAuthorship W3204165978A5040357304 @default.
• W3204165978 hasAuthorship W3204165978A5040571502 @default.
• W3204165978 hasAuthorship W3204165978A5062655427 @default.
• W3204165978 hasAuthorship W3204165978A5067292776 @default.
• W3204165978 hasAuthorship W3204165978A5073488481 @default.
• W3204165978 hasBestOaLocation W32041659781 @default.
• W3204165978 hasConcept C183713625 @default.
• W3204165978 hasConcept C190283241 @default.
• W3204165978 hasConcept C2775934118 @default.
• W3204165978 hasConcept C2776715637 @default.
• W3204165978 hasConcept C2776820818 @default.
• W3204165978 hasConcept C29537977 @default.
• W3204165978 hasConcept C31573885 @default.
• W3204165978 hasConcept C43060935 @default.
• W3204165978 hasConcept C502942594 @default.
• W3204165978 hasConcept C54355233 @default.
• W3204165978 hasConcept C55493867 @default.
• W3204165978 hasConcept C62112901 @default.
• W3204165978 hasConcept C62478195 @default.
• W3204165978 hasConcept C81885089 @default.
• W3204165978 hasConcept C86554907 @default.
• W3204165978 hasConcept C86803240 @default.
• W3204165978 hasConcept C95444343 @default.
• W3204165978 hasConceptScore W3204165978C183713625 @default.
• W3204165978 hasConceptScore W3204165978C190283241 @default.
• W3204165978 hasConceptScore W3204165978C2775934118 @default.
• W3204165978 hasConceptScore W3204165978C2776715637 @default.
• W3204165978 hasConceptScore W3204165978C2776820818 @default.

• next